Q3: 2026-11-11 Earnings Summary
EPS of -$0.03 beats by $0.02
| Revenue of $111.56M (-2.02% Y/Y) misses by $16.84M
Alvotech (ALVO) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST
Company Participants
Robert Wessman – Founder & Executive Chairman
Balaji Prasad – Chief Strategy Officer
Conference Call Participants
Ashwani Verma – UBS Investment Bank, Research Division
Presentation
Ashwani Verma
UBS Investment Bank, Research Division
All right. Good day, everybody. Welcome to UBS Biopharma conference in London. Next company with me here Alvotech. My name is Ash Verma. I cover SMID biotech and spec pharma and we have Robert and Balaji from Alvotech. Thank you so much for joining us today.
Robert Wessman
Founder & Executive Chairman
Yes, thank you, Ash. Pleasure.
Ashwani Verma
UBS Investment Bank, Research Division
Yes. So a lot of exciting things going on with Alvotech, maybe I think most people are kind of familiar with the story, but if you can just kind of remind like what the pure-play biosimilar and talk about some of the programs.
Robert Wessman
Founder & Executive Chairman
Yes. I mean yes, exactly. I founded the company 2013. I mean we knew that biologic would be the future of pharmacy development, if you will. I mean those medications, as we all know, are quite effective, but very expensive. So we predicted that there would be a very strong need for a company like ours, post 2020. So the concept was always played biosimilar having end-to-end R&D end-to-end manufacturing from vial fill to finished products, both drug substance, fill-finish, sterile. Then we do even assembly of our autoinjector.
And then we have built out the commercial network now with 20 different partners, including Teva in U.S. and Advanz and STADA in Europe. And we have invested now over $2 billion into building the infrastructure. And we have super pulp because — we believe that we have 1 of the largest pipeline in hub developed pipeline in
